Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

BACKGROUND: Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Pivotal Trial in Melanoma study, which also included patients with distant metastases and...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunother Cancer
Päätekijät: Ressler, Julia Maria, Karasek, Matthias, Koch, Lukas, Silmbrod, Rita, Mangana, Joanna, Latifyan, Sofiya, Aedo-Lopez, Veronica, Kehrer, Helmut, Weihsengruber, Felix, Koelblinger, Peter, Posch, Christian, Kofler, Julian, Michielin, Olivier, Richtig, Erika, Hafner, Christine, Hoeller, Christoph
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2021
Aiheet:
Oncolytic and Local Immunotherapy
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7898852/
https://ncbi.nlm.nih.gov/pubmed/33608376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001701
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia